RxDoctor Payments Data

Shannon Brow

Nurse Practitioner · Houston, TXNPI 1558540930

Payments from drug & device makers

$3,452in general payments, 2019–2025

Across 81 payments — averaging $42.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$938
  • AstraZeneca$528
  • Amgen$339
  • Aurinia Pharma U.S., Inc.$236
  • AbbVie$193
  • Otsuka America Pharmaceutical, Inc.$183
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,452100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,452 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban19$25,957
JardianceEmpagliflozin16$24,918
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/716$24,376
FarxigaDapagliflozin Propanediol13$18,087
MounjaroTirzepatide15$16,640
Tresiba Flextouch U-100Insulin Degludec20$10,191
Ultra-Fine Short Pen NeedlePen Needle, Diabetic23$2,063
Novolog FlexpenInsulin Aspart11$1,725
Rosuvastatin Calcium86$1,226
Omeprazole40$773
Gabapentin29$628
Fluticasone Propionate17$364
Metoprolol Succinate33$333
Lisinopril64$316
FenofibrateFenofibrate,micronized12$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$146$24,91816 claims
AstraZenecaFarxiga$528$18,08713 claims
Lilly USA, LLCMounjaro$38$16,64015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →